L Parker Gregg1,2, Nishank Jain3,4, Thomas Carmody5,6, Abu T Minhajuddin5, A John Rush7, Madhukar H Trivedi6, S Susan Hedayati8. 1. Division of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 2. Renal Section, Medical Service, Veterans Affairs North Texas Health Care System, Dallas, Texas, USA. 3. Division of Nephrology, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. 4. Division of Nephrology, Department of Medicine, CentralArkansas Veterans Affairs Health Care System, Little Rock, Arkansas, USA. 5. Division of Biostatistics, Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 6. Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 7. Division of Clinical Sciences, Duke-NUS, Singapore, Singapore. 8. Division of Nephrology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA, susan.hedayati@utsouthwestern.edu.
Abstract
BACKGROUND: Fatigue, although common and associated with outcomes in dialysis-dependent chronic kidney disease (CKD), has not been studied in nondialysis chronic kidney disease (CKD-ND) patients. METHODS: In this longitudinal cohort of 266 outpatients with CKD-ND stages 2-5, we measured self-reported fatigue on 3 scales-Quick Inventory of Depression Symptomatology-Self Report (QIDS-SR16), Beck Depression Inventory-I (BDI-I), and short form 12 health survey (SF-12) questionnaires and evaluated the prespecified composite of progression to dialysis initiation, death, or hospitalization after 12 months. Logistic and linear regression assessed characteristics associated with fatigue. Survival analysis measured associations of fatigue with outcomes. RESULTS: Mean age was 64.4 ± 12.0 years, and mean estimated glomerular filtration rate (eGFR) was 31.6 ± 16.7 mL/min/1.73 m2. Fatigue was common, with 69.2% reporting fatigue on QIDS-SR16 and 77.7% on BDI-I. Unemployment, comorbidities, use of antidepressant medications, and lower hemoglobin correlated with fatigue. There were 126 outcome events. Participants that reported any versus no fatigue on QIDS-SR16 were more likely to reach the composite, hazard ratio (HR) 1.70 (95% CI 1.11-2.59), which persisted after adjusting for demographics, comorbidities, substance abuse, hemoglobin, albumin, eGFR, and calcium-phosphorus product, HR 1.63 (1.05-2.55). Fatigue severity by the SF-12 was also associated with outcomes independent of demographics, comorbidities, and substance abuse, HR per unit increase 1.18 (1.03-1.35). No association was observed with fatigue on the BDI-I. CONCLUSION: Fatigue affected about 2/3 of CKD-ND patients and associated with unemployment, comorbidities, antidepressant medication use, and anemia. Fatigue measured by the QIDS-SR16 and SF-12 independently predicted outcomes in CKD patients. Eliciting the presence of fatigue may be a clinically significant prognostic assessment in CKD patients.
BACKGROUND:Fatigue, although common and associated with outcomes in dialysis-dependent chronic kidney disease (CKD), has not been studied in nondialysis chronic kidney disease (CKD-ND) patients. METHODS: In this longitudinal cohort of 266 outpatients with CKD-ND stages 2-5, we measured self-reported fatigue on 3 scales-Quick Inventory of Depression Symptomatology-Self Report (QIDS-SR16), Beck Depression Inventory-I (BDI-I), and short form 12 health survey (SF-12) questionnaires and evaluated the prespecified composite of progression to dialysis initiation, death, or hospitalization after 12 months. Logistic and linear regression assessed characteristics associated with fatigue. Survival analysis measured associations of fatigue with outcomes. RESULTS: Mean age was 64.4 ± 12.0 years, and mean estimated glomerular filtration rate (eGFR) was 31.6 ± 16.7 mL/min/1.73 m2. Fatigue was common, with 69.2% reporting fatigue on QIDS-SR16 and 77.7% on BDI-I. Unemployment, comorbidities, use of antidepressant medications, and lower hemoglobin correlated with fatigue. There were 126 outcome events. Participants that reported any versus no fatigue on QIDS-SR16 were more likely to reach the composite, hazard ratio (HR) 1.70 (95% CI 1.11-2.59), which persisted after adjusting for demographics, comorbidities, substance abuse, hemoglobin, albumin, eGFR, and calcium-phosphorus product, HR 1.63 (1.05-2.55). Fatigue severity by the SF-12 was also associated with outcomes independent of demographics, comorbidities, and substance abuse, HR per unit increase 1.18 (1.03-1.35). No association was observed with fatigue on the BDI-I. CONCLUSION:Fatigue affected about 2/3 of CKD-NDpatients and associated with unemployment, comorbidities, antidepressant medication use, and anemia. Fatigue measured by the QIDS-SR16 and SF-12 independently predicted outcomes in CKDpatients. Eliciting the presence of fatigue may be a clinically significant prognostic assessment in CKDpatients.
Authors: Sarah Barnes; Merryn Gott; Sheila Payne; Chris Parker; David Seamark; Salah Gariballa; Neil Small Journal: J Pain Symptom Manage Date: 2006-09 Impact factor: 3.612
Authors: M H Trivedi; A J Rush; H M Ibrahim; T J Carmody; M M Biggs; T Suppes; M L Crismon; K Shores-Wilson; M G Toprac; E B Dennehy; B Witte; T M Kashner Journal: Psychol Med Date: 2004-01 Impact factor: 7.723
Authors: S Susan Hedayati; Abu T Minhajuddin; Robert D Toto; David W Morris; A John Rush Journal: Am J Kidney Dis Date: 2009-06-03 Impact factor: 8.860
Authors: Steven D Weisbord; Sharon S Carmody; Frank J Bruns; Armando J Rotondi; Lewis M Cohen; Mark L Zeidel; Robert M Arnold Journal: Nephrol Dial Transplant Date: 2003-07 Impact factor: 5.992
Authors: Glen James; Elisabeth Nyman; Marcy Fitz-Randolph; Anna Niklasson; Katarina Hedman; Jonatan Hedberg; Eric T Wittbrodt; Jennie Medin; Carol Moreno Quinn; Alaster M Allum; Cathy Emmas Journal: J Med Internet Res Date: 2020-07-15 Impact factor: 5.428
Authors: A C Nixon; T J Wilkinson; H M L Young; M W Taal; N Pendleton; S Mitra; M E Brady; A P Dhaygude; A C Smith Journal: BMC Nephrol Date: 2020-09-23 Impact factor: 2.388